Alnylam Pharmaceuticals Inc logo

ALNY - Alnylam Pharmaceuticals Inc Share Price

$114.28 2.1  1.9%

Last Trade - 5:15pm

Sector
Healthcare
Size
Large Cap
Market Cap £10.37bn
Enterprise Value £9.11bn
Revenue £179.7m
Position in Universe 513th / 6312
Bullish
Bearish
Unlock ALNY Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALNY Revenue Unlock ALNY Revenue

Net Income

ALNY Net Income Unlock ALNY Revenue

Normalised EPS

ALNY Normalised EPS Unlock ALNY Revenue

PE Ratio Range

ALNY PE Ratio Range Unlock ALNY Revenue

Dividend Yield Range

ALNY Dividend Yield Range Unlock ALNY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALNY EPS Forecasts Unlock ALNY Revenue
Profile Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated May 8, 2003
Public Since May 28, 2004
No. of Shareholders: 29
No. of Employees: 1,323
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 113,072,381
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALNY Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALNY
Upcoming Events for ALNY
Tuesday 14th April, 2020
Alnylam Pharmaceuticals Inc at Needham Healthcare Conference
Friday 24th April, 2020 Estimate
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting
Wednesday 29th April, 2020 Estimate
Q1 2020 Alnylam Pharmaceuticals Inc Earnings Release
Wednesday 6th May, 2020
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting
Tuesday 4th August, 2020 Estimate
Q2 2020 Alnylam Pharmaceuticals Inc Earnings Release
Similar to ALNY
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.